Yahoo
NasdaqGS - Nasdaq Real Time Price USD

C4 Therapeutics, Inc. (CCCC)

3.9991 +0.0791 (+2.02%)
As of 12:46:08 PM EDT. Market Open.
Trade CCCC on Coinbase
Chart Range Bar
Loading chart for CCCC
  • Previous Close 3.9200
  • Open 4.0000
  • Bid 2.9400 x 200
  • Ask 4.9900 x 200
  • Day's Range 3.8550 - 4.1700
  • 52 Week Range 1.3600 - 4.5980
  • Volume 1,350,462
  • Avg. Volume 2,749,617
  • Market Cap (intraday) 442.169M
  • Beta (5Y Monthly) 2.93
  • PE Ratio (TTM) --
  • EPS (TTM) -1.1000
  • Earnings Date (est.) Aug 6, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 13.33

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

www.c4therapeutics.com

104

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 6/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CCCC
109.38%
S&P 500 (^GSPC)
9.55%

1-Year Return

CCCC
177.72%
S&P 500 (^GSPC)
25.39%

3-Year Return

CCCC
18.67%
S&P 500 (^GSPC)
70.07%

5-Year Return

CCCC
89.45%
S&P 500 (^GSPC)
80.00%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 6.15M
Earnings -25.13M

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-20M
-10M
0
10M

Analyst Insights

View More

Analyst Price Targets

7.00
13.33 Average
3.9991 Current
30.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 6/1/2026
Analyst Evercore ISI Group
Rating Action Maintains
Rating Outperform
Price Action Raises
Price Target 7 -> 12

Statistics

View More

Valuation Measures

Annual
As of 6/17/2026
  • Market Cap

    432.32M

  • Enterprise Value

    255.09M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    10.85

  • Price/Book (mrq)

    1.85

  • Enterprise Value/Revenue

    7.32

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -297.76%

  • Return on Assets (ttm)

    -19.88%

  • Return on Equity (ttm)

    -48.35%

  • Revenue (ttm)

    34.86M

  • Net Income Avi to Common (ttm)

    -103.8M

  • Diluted EPS (ttm)

    -1.1000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    235.67M

  • Total Debt/Equity (mrq)

    24.95%

  • Levered Free Cash Flow (ttm)

    -53.37M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

3.9991 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: